Literature DB >> 15651616

Dosimetric study of the 15 mm ROPES eye plaque.

D Granero1, J Pérez-Calatayud, F Ballester, E Casal, J M de Frutos.   

Abstract

The main aim of this paper is to make a study of dose-rate distributions obtained around the 15 mm, radiation oncology physics and engineering services, Australia (ROPES) eye plaque loaded with 125I model 6711 radioactive seeds. In this study, we have carried out a comparison of the dose-rate distributions obtained by the algorithm used by the Plaque Simulator (PS) (BEBIG GmbH, Berlin, Germany) treatment planning system with those obtained by means of the Monte Carlo method for the ROPES eye plaque. A simple method to obtain the dose-rate distributions in a treatment planning system via the superposition of the dose-rate distributions of a seed placed in the eye plaque has been developed. The method uses eye plaque located in a simplified geometry of the head anatomy and distributions obtained by means of the Monte Carlo code GEANT4. The favorable results obtained in the development of this method suggest that it could be implemented on a treatment planning system to improve dose-rate calculations. We have also found that the dose-rate falls sharply along the eye and that outside the eye the dose-rate is very low. Furthermore, the lack of backscatter photons from the air located outside the eye-head phantom produces a dose reduction negligible for distances from the eye-plaque r<1 cm but reaches up to 20% near the air-eye interface. Results showed that the treatment planning system lacks accuracy around the border of the eye (in the sclera and the surrounding area) due to the simplicity of the algorithm used. The BEBIG treatment planning system uses a global attenuation factor that takes into account the effect of the eye plaque seed carrier and the lack of backscatter photons caused by the metallic cover, which in the case of a ROPES eye plaque has a default value of T= 1 (no correction). In the present study, a global attenuation factor T=0.96 and an air-interface correction factor which improve on treatment planning system calculations were obtained.

Mesh:

Substances:

Year:  2004        PMID: 15651616     DOI: 10.1118/1.1812605

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  6 in total

1.  Visual outcome after posterior uveal melanoma episcleral brachytherapy including radiobiological doses.

Authors:  David Miguel; Jesús María de Frutos-Baraja; Francisco López-Lara; María Antonia Saornil; Ciro García-Alvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2018-04-30

2.  Radiobiological doses, tumor, and treatment features influence on local control, enucleation rates, and survival after epiescleral brachytherapy. A 20-year retrospective analysis from a single-institution: part I.

Authors:  David Miguel; Jesús María de Frutos-Baraja; Francisco López-Lara; María Antonia Saornil; Ciro García-Álvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2018-08-31

3.  Regression of posterior uveal melanoma following iodine-125 plaque radiotherapy based on pre-treatment tumor apical height.

Authors:  David Miguel; María Antonia Saornil; Jesús María de Frutos; Ciro García-Álvarez; Pilar Alonso; Patricia Diezhandino
Journal:  J Contemp Brachytherapy       Date:  2021-04-14

4.  Keeping an eye on the ring: COMS plaque loading optimization for improved dose conformity and homogeneity.

Authors:  Nolan L Gagne; Daniel R Cutright; Mark J Rivard
Journal:  J Contemp Brachytherapy       Date:  2012-09-29

5.  Bilateral episcleral brachytherapy in simultaneous choroidal melanoma and circumscribed hemangioma.

Authors:  María Encarnación Correa-Pérez; María Antonia Saornil; Ciro García-Álvarez; Francisco Lopez-Lara Martín; Jesus María Frutos-Baraja
Journal:  J Contemp Brachytherapy       Date:  2013-10-28

6.  Comparison of 16 mm OSU-Nag and COMS eye plaques.

Authors:  Hualin Zhang; Frederick Davidorf; Yujin Qi
Journal:  J Appl Clin Med Phys       Date:  2012-05-10       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.